Table 1 Clinicopathological findings and surgical outcomes of the low and high intratumoral FAP groups

Age [years; median (IQR)]

70 (64.3–75.5)

71 (63.5–76.0)

0.837

Gender, n (%)

0.275

Female

5 (50.0)

8 (29.6)

Male

5 (50.0)

19 (70.4)

History of hepatitis B infection, n (%)

2 (20.0)

8 (29.6)

0.694

History of hepatitis C infection, n (%)

1 (10.0)

4 (14.8)

1.000

CEA [mg/dL; median (IQR)]

2.70 (1.83–8.63)

2.60 (1.50–5.75)

0.656

CA19-9 [mg/dL; median (IQR)]

28.5 (10.0–95.0)

187.0 (15.5–1016.0)

0.171

Type of hepatectomy, n (%)

0.921

Hr0

1 (10.0)

1 (3.7)

Hr1

2 (20.0)

6 (22.2)

Hr2

6 (60.0)

17v(63.0)

Hr3

1 (10.0)

3 (11.1)

Lymph nodes dissection

0.881

D0

6 (60.0)

13 (48.1)

D2 or D2+

4 (40.0)

14 (51.9)

Operation time [min; median (IQR)]

324.0 (275.5-353.8)

344.0 (287.0-438.0)

0.365

Blood loss [mL; median (IQR)]

122.5 (111.0-204.2)

285 (159.5-576.5)

0.067

All complications, yes, n (%)

1 (10.0)

6 (22.2)

0.647

Pathological tumor size

[mm; median (IQR)]

54.0 (41.8–60.0)

35.0 (28.5–51.5)

0.057

Pathological T stage ^a, n (%)

0.098

pT1

0 (0)

1 (3.7)

pT2

7 (70.0)

7 (25.9)

pT3

3 (30.0)

15 (55.5)

pT4

0 (0.0)

4 (14.8)

Pathological N stage ^a, n (%)

0.393

pN0

9 (90.0)

19 (70.3)

pN1

1 (10.0)

1 (3.7)

Pathological stage ^a, n (%)

0.036*

I

0 (0.0)

1 (3.7)

II

7 (70.0)

5 (18.5)

III

2 (20.0)

11 (40.7)

IV

1 (10.0)

10 (37.0)

Curability ^a, n (%)

0.023*

A

7 (70.0)

7 (25.9)

B

3 (30.0)

20 (74.1)

Adjuvant chemotherapy, yes, n (%)

1 (10.0)

6 (22.2)

0.647

Peripheral region

FAP (%)

38.4 (30.6–22.4)

15.5 (11.7–22.4)

0.296

SMA (%)

12.7 (11.5–14.1)

14.5 (12.7–19.2)

0.105

Intratumoral region

SMA (%)

8.28 (5.94–13.8)

9.95 (8.23-13.0)

0.408